Embla Medical Hf S/Adr (OSSUY) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to EMPLA Medical Conference Call for Q2 2025. Today's call is being recorded. If you have any objections, please disconnect at this time. All participants will be in a listen-only mode throughout the presentation. Afterwards, there will be a question and answer session. To ask a question, please press 5 star on your telephone keypad. I would now like to introduce President and CEO Svend Sulvason and CFO Arne Svensdottir. Please begin your presentation. Thank you very much, and good morning, and welcome to the Ampla Medical Conference Call, where we will review the second quarter of 2025. I'm Fred Sjölandson, President and CEO of Ampla Medical. Joining me on today's call is our Chief Financial Officer, Arne Svensdorf, and Ampla Medical's Head of the Investor Relations, Klaus Sinter. The presentation should take approximately 15 minutes, after which there will be an opportunity to ask questions during a Q&A session. If we go to the next slide, please. Sales in the second quarter amounted to 232 million, representing 7% reported growth, of which 5% was organic. Growth was strong in the prosthetics and neuro-orthotics segment, mainly driven by the continued momentum in MEA, and supported by solid contributions from our recently launched innovation. Growth in Americas and APAC was also good, led by the prosthetics and neuro-orthotics segment, while sales in patient care remained flat. Sales in bracing and support experienced a slight decline. The EBITDA margin was strong at 21% and 20% for the first half of the year, compared to 19% in the first half of 2024. The margin increase for the first half was driven by robust sales in prosthetics and neuro-orthotics, solid efficiency in manufacturing, and continued cost-disadvantaged G&A. In line with sales performance in...